Aims: Renal cell carcinoma, unclassified (RCCU) is a category that includes a morphologically and biologically heterogeneous group of tumours that are unable to be diagnosed as other well-defined entities. We aim to describe the morphological findings of tumours within this category and to determine the most frequent morphological features leading to classification difficulty. Methods and results: One hundred and thirty-six cases of RCCU were examined. Patients ranged in age from 23 to 87 years. Seventy-seven patients were men and 59 were women. International Society of Urological Pathology (ISUP) grade was most commonly 3 (n = 66), followed by 2 (n = 42) and 4 (n = 28). Tumour size ranged from 0.6 to 24.9 cm. The American Joint Committee on Cancer (AJCC) pathological T categories included pT1a (n = 50), pT1b (n = 14), pT2a (n = 7), pT2b (n = 4), pT3a (n = 50) and pT4 (n = 9). Forty-four cases included lymph node(s), 41% of which (n = 18) had metastases. Tumours were assessed for a variety of histological features and assigned to the following morphological groups: predominantly oncocytoma/ chromophobe RCC-like; clear cell RCC-like; papillary RCC-like; collecting duct-like; and pure sarcomatoid differentiation. The majority of the oncocytoma/chromophobe and clear cell RCC-like phenotypes were low stage (pT1 or pT2). The papillary RCC-like, collecting duct-like and pure sarcomatoid phenotypes were mainly high stage (pT3 or pT4). Conclusions: Renal cell carcinoma, unclassified is a term that encompasses tumours with a variety of morphological features and a wide biological spectrum. The most common source of diagnostic difficulty was tumours composed of predominantly eosinophilic cells.
Introduction
Renal epithelial tumours that do not fit into any of the defined entities in the 2016 World Health Organisation classification are diagnosed generally as renal cell carcinoma, unclassified (RCCU). 1 This category may include tumours with unique morphological patterns that fall outside the known categories, have overlapping features of known subtypes or are pure sarcomatoid tumours demonstrated to be of epithelial derivation. 1, 2 In practice, it can be difficult for the pathologist to decide exactly which or how many features do not allow a case to be assigned a more specific diagnosis. Adding to this dilemma, these tumours comprise a small proportion of renal cell carcinomas (<5%) and occur in patients of all ages. Therefore, pathologists in any setting can encounter them, but individual experience with RCCU may be limited. [1] [2] [3] [4] Overall, in contemporary series, most renal cell carcinomas (RCC) are low stage (pT1 and pT2, 73.5% versus pT3 and pT4, 26.5%) and low nuclear grade (Fuhrman grades 1 or 2, 61% versus 3 or 4, 32%). 5 A number of studies addressing the prognosis of RCCU have reported that this diagnosis portends a worse outcome, giving the impression that these lesions are uniformly high grade and high stage. [6] [7] [8] [9] [10] The many unknowns surrounding tumours diagnosed as RCCU will probably be elucidated over time as distinct diagnostic entities emerge from this group. Only one comprehensive molecular study has been published to date in an attempt to understand these lesions further, and it underlined the heterogeneity of this category. The authors applied multiple molecular assays to 62 cases, detected recurrent somatic mutations in 29 genes and outlined multiple different potential molecular subtypes (NF2 loss, mTORC1 hyperactive, FH-deficient, ALK translocation) with differing clinical outcomes. 11 The purpose of this study is to describe the morphological spectrum of RCCU in 136 cases diagnosed at our institution. We assigned each tumour to one of several morphological groups in order to describe the main histopathological features that present problems when attempting to classify primary renal epithelial tumours. We also report the basic epidemiological data, American Joint Committee on Cancer (AJCC) pathological tumour-node-metastasis (TNM) categories, and pertinent findings in the adjacent uninvolved kidney. We hope that this paper emphasises further the heterogeneity of this category.
Materials and methods
The pathology database at our institution was queried for cases with a final diagnosis of 'renal cell carcinoma, unclassified' or 'renal cell carcinoma, not otherwise specified' between July 2007 and September 2016. Cases were included in this study from the queried time-frame only if slides were available for re-review. Needle biopsy cases were excluded. A total of 136 cases were found that met these criteria. Most cases had been reported by (97%, 132 of 136), and all cases documented review by pathologists with a subspeciality interest in urological pathology. This study was approved by the Institutional Review Board.
Haematoxylin and eosin-stained slides were reviewed and the tumours were classified according to the 2016 World Health Organisation classification system. 1 The 2010 AJCC TNM classification system was used for pathological staging. 12 An International Society of Urological Pathology (ISUP) grade was assigned to each tumour. 13 Pathology reports were reviewed and data were collected including patient age, sex, specimen type and pathological TNM stage. All available slides were reviewed and the presence or absence of 36 different morphological features was recorded for each case. In addition, the predominant morphological pattern was noted for each case. These patterns included: predominantly oncocytoma/chromophobe RCC-like phenotype, predominantly papillary RCC-like phenotype, predominantly clear cell RCC-like phenotype, predominantly collecting duct-like phenotype and pure sarcomatoid phenotype. The oncocytoma/chromophobe RCC-like category consisted of tumours that were composed mainly of sheets and/or nests of cells with eosinophilic cytoplasm; however, focal papillary architecture was seen occasionally. The top differential diagnoses in this category were mainly eosinophilic chromophobe RCC versus oncocytoma. In the papillary RCC-like category the majority of neoplastic cells lined fibrovascular cores. The main differential diagnoses were papillary RCC versus translocation-associated RCC. Tumours in the clear cell RCC-like category consisted mainly of cells with abundant, clear cytoplasm with a delicate, 'chicken-wire' vasculature; focal granular, eosinophilic cytoplasm was permitted. The main differential diagnoses were clear cell RCC, translocation-associated RCC and clear cell papillary RCC. Collecting duct-like phenotype included cases with high-grade cytology, tubulopapillary architecture and desmoplastic stroma. The main differential diagnoses were collecting duct carcinoma, medullary carcinoma and urothelial carcinoma. For each of these four categories individual cases had one or more morphological features that were considered sufficiently unusual as to exclude definitive classification. The pure sarcomatoid category consists of cells composed entirely of spindle-shaped cells without any epithelioid elements. Of note, an AJCC pathological TNM stage could not be assigned to two tumours that were consultations with only select slides available for re-review.
Results
Among the 136 cases included in this study, 66% (90 of 136) were from radical nephrectomy, 33% (45 of 136) were from partial nephrectomy and 1% (one of 136) was from a nephroureterectomy specimen.
The majority of cases were resected at our institution (71%, 97 of 136), versus 27% (36 of 136) that were personal consultation cases.
The 136 cases were from 136 different patients, 77 male and 59 female, who ranged in age from 23 to 87 years (median age: 61 years). The uninvolved kidney was unremarkable (n = 103) or only had simple cortical cysts (n = 21) in 91% (124 of 136) of cases. The uninvolved kidney had end-stage renal disease and/or acquired cystic kidney disease in 6% (eight of 136) of cases. A horseshoe kidney was present in one case. Other minor findings were noted, including infarct (n = 3), ectopic adrenal gland (n = 1) and a calcified fibrotic nodule (n = 1).
The ISUP grade was 2 for 31% (42 of 136), 3 for 49% (66 of 136) and 4 for 21% (28 of 136) of tumours. The tumours ranged in size from 0.6 to 24.9 cm (median size: 5 cm). Most tumours were unifocal (90%, 123 of 136). A minority of tumours were multifocal (9%, 12 of 136), all of which had two or three separate foci of tumour. Focality was not specified in one consultation case with limited slides available for re-review. Sarcomatoid differentiation was present in 9% (12 of 136) of cases.
In addition to RCCU, between one and five other neoplastic lesions were seen in 15% (21 of 136) of cases. These were most frequently a papillary adenoma (n = 9), followed by papillary RCC (n = 5), clear cell RCC (n = 3), angiomyolipoma (n = 3), renomedullary interstitial cell tumour (n = 3), chromophobe RCC (n = 1), acquired cystic disease-associated RCC (n = 1), multilocular cystic renal neoplasm of low malignant potential (n = 1) and metanephric adenoma (n = 1).
Among all specimens with a pathological TNM stage assigned (n = 134), the most common pT categories were pT3a (37%, 50 of 134) and pT1a (37%, 50 of 134) ( Table 1) . Overall, approximately half the cases were organ confined (pT1a, pT1b, pT2a or pT2b; 56%, 75 of 134), whereas the remaining 44% (50 of 134) were pT3a (n = 41) or pT4 (n = 9). Lymph node metastases were present in 41% (18 of 44) of cases with lymph nodes present. Among these cases, most were pT3a (61%, 11 of 18) or pT4 (33%, six of 8), and only one case was assigned a low pT category (pT1b). Distant metastases were documented in four cases, three of which were to the adrenal gland and one was to the liver. 
For the entire group of tumours included in the study, the presence of eosinophilic cytoplasm in at least some tumour cells was the most commonly observed morphological feature and was present in 83% (113 of 136) of cases ( . There were eight cases with two or more clearly defined morphological areas that were juxtaposed abruptly, rather than intermingled intimately. Each of the tumours was assigned to one morphological category depending on the predominant pattern observed on re-review ( Table 3 ). The most commonly assigned patterns were predominantly oncocytoma/chromophobe RCC-like phenotype (73%, 99 of 136), predominantly clear cell RCC-like phenotype (14%, 19 of 136) and predominantly papillary RCC-like phenotype (9%, 12 of 136) (Figures 3, 4 and 5). In reality, there was a great deal of overlapping morphology in these tumours, therefore the purpose of assigning a predominant pattern was to determine if there was an overall trend showing which patterns were most challenging diagnostically. For example, tumours with features of translocationassociated RCC have both eosinophilic cytoplasm and papillary architecture and were placed mainly in the papillary RCC-like group.
Among cases with an oncocytoma/chromophobe RCC-like phenotype as their primary pattern, 31% (31 of 99) were consults, 68% (69 of 99) institutional cases, 36% (36 of 99) partial nephrectomies and 64% (63 of 99) radical nephrectomies. ISUP grade was 2 in 34% (34 of 99) and 3 or 4 in 66% (65 of 99) of cases. AJCC pathological TNM stage was not assigned to two cases, given that they were consultations with only select slides available for re-review. AJCC pT category was pT1a in 39% (38 of 97), pT1b in 10% (10 of 97), pT2a in 6% (six of 97), pT2b in 4% (four of 97), pT3a in 36% (35 of 97) and pT4 in 4% (four of 97) of cases. AJCC pN category was pN1 in 9% (nine of 97) of cases. Three cases were AJCC pM category pM1.
Although the number of cases was too small to draw statistically significant conclusions, the AJCC pT category varied depending on the morphological subtype assigned ( Figure 6 ). However, given that outcome data were not available for many cases, we are unable to corroborate these findings further. Pathological category pT1 and pT2 tumours were considered low stage, whereas pT3 and pT4 tumours were considered high stage. When dividing cases into high and low stage, three main 'types' of tumours emerged. The oncocytoma/chromophobe RCC-like phenotype was considered group I, the clear cell RCClike phenotype group II and papillary RCC-like/collecting duct/pure sarcomatoid tumours were group III. Groups I and II tumours both contained more low-stage (58 of 99, 59% and 12 of 19, 63%, respectively) than high-stage tumours. Overall, group III tumours were more commonly high stage (72%, 13 of 18). Specifically, the papillary RCC-like group contained more high-stage (seven of 12, 58%) than lowstage tumours, but this difference was minimal. The collecting duct-like and pure sarcomatoid phenotypes contained only high-stage tumours (six of six, 100%).
Among tumours in the oncocytoma/chromophobe RCC-like phenotype that were pT3 (n = 35), perinephric fat invasion was present in 69% (24 of 35), renal sinus fat invasion in 66% (23 of 35) and renal vein invasion in 54% (19 of 35) .
Among tumours in the papillary RCC-like phenotype that were pT3 (n = 4), perinephric fat invasion was present in 0% (none of four), renal sinus fat invasion in 100% (four of four) and renal vein invasion in 25% (one of four). Among tumours in the collecting duct-like phenotype that were pT3 (n = 3), perinephric fat invasion was present in 100% (three of three), renal sinus fat invasion in 67% (two of three) and renal vein invasion in 33% (one of three). Among tumours in the clear cell-like phenotype that were pT3 (n = 7), perinephric fat invasion was present in 43% (three of seven), renal sinus fat invasion in 57% (four of seven) and renal vein invasion in 71% (five of seven).
The incidences of lymph node metastasis were 12, 7 and 44%, respectively, in groups 1, 2 and 3 RCCU ( Figure 7 , Table 3 ). Interestingly, none of these tumours with lymph node metastasis contained 'oncocytic' cells.
Discussion
Renal cell carcinoma, unclassified is a diagnosis that is recommended for 'tumours that do not readily fit into any of the recognised subtypes of RCC' according to the 2016 World Health Organisation Classification. 1 This category also includes 'low-grade . . . unclassified oncocytic neoplasms' where the differential diagnosis would include oncocytoma, a benign entity. The growing awareness of emerging RCC subtypes and increasing utilisation of immunohistochemical stains and ancillary studies may also contribute to an increasing use of this category in practice. Similarly, variability between pathologists and institutions regarding stringency of diagnostic criteria for each category of RCC may also play a role in the frequency that this category is assigned.
Very few studies have attempted to describe the morphological features present in tumours diagnosed as RCCU. One study found that microvascular invasion, necrosis, tumour size and histotype were independent predictors of disease-free survival on multivariate analysis.
14 Although this study defined 'histotype' as either unrecognised cell type, a composite of recognised cell types or pure sarcomatoid differentiation, the authors did not include further explanation of these categories or photomicrographs of the tumours.
14 Talento et al. described the ultrastructural findings in 10 cases of RCCU as supporting an epithelial and possible lower nephron origin; Fibrous capsule/ pseudocapsule 10 (7) 7 (7) Desmoplastic stroma 9 (7) 3 (3) Foamy macrophages 7 (5) 6 (6) Thick-walled vessels 7 (5) 7 however a description of the findings of the haematoxylin and eosin-stained slides is limited to 'unrecognisable cell types'. 15 Most studies have reported that the histological subtype of RCC is an independent predictor of outcome, and the literature is dominated by studies which state that RCCU has a poor prognosis compared to other RCC subtypes. [6] [7] [8] [9] [10] [16] [17] [18] Many of these studies did not have slides re-reviewed by a pathologist, had an absence of RCCU tumours that were low grade and low stage and did not exclude tumours with sarcomatoid differentiation (shown to portend a worse prognosis regardless of concomitant subtype of RCC). 19 In one such study, 71% (60 of 85) of the RCCU cases were high stage (pT3 or pT4) versus 38% (1624 of 4322) of clear cell RCC cases and 80% (68 of 85) of RCCU cases were high Fuhrman nuclear grade (3 or 4) compared to 38% (1632 of 4322) of the clear cell RCC cases. 6 Another study matched RCCU cases with clear cell RCC cases stage for stage, but 100% (19 of 19) of RCCU cases versus 52% (148 of 256) of clear cell RCC cases were Fuhrman nuclear grades 3 or 4.
8 A third study did not have RCCU cases re-reviewed, and therefore did not include Fuhrman nuclear grade, as at their institution this is reported only for clear cell RCC. 7 Recently, Kuthi et al. applied the 2016 WHO renal tumour classification to 928 nephrectomies and reported that RCCU (n = 28; 3%) had a lower 5-year cancer-specific survival rate compared to clear cell RCC (46% versus 83%). Most RCCU tumours were ISUP grades 3 or 4 (77%), had sarcomatoid/rhabdoid differentiation (41%) and were AJCC pT categories pT3a or pT3b (68%). 20 A study of 5339 cases of RCC (clear cell, papillary, chromophobe, collecting duct, unclassified) from all patients undergoing radical or partial nephrectomy (1995-2007) at 16 different academic centres in Italy showed that most tumours were low stage and low grade (pT1 and pT2, 73.5 versus pT3 and pT4, 26.5%). 5 While these authors found that 73.5% of tumours were low stage, in the current series 56% (75 of 134) of RCCU tumours were low stage. Conversely, 26 .5% of all tumours in the series were high stage, compared to 43% (59 of 136) in the current cohort of RCCU. Most tumours from this large overall RCC cohort (51%) were low nuclear grade, compared to only 31% in the current series (69% high nuclear grade). 5 In our cohort, renal neoplasms composed predominantly of cells with eosinophilic cytoplasm posed the greatest diagnostic challenge. On re-review, cells with eosinophilic cytoplasm were present in 83% (113 of 136) of cases, and the oncocytoma/chromophobe RCC-like phenotype was the most commonly assigned primary pattern (73%, 99 of 136). Features of oncocytoma (oncocytic cells, 32%; loose hypocellular stroma, 28%; entrapped non-neoplastic renal tubules, 17%) and chromophobe RCC (prominent cell borders, 20%; perinuclear halos, 14%; thick-walled vessels, 7%) were observed commonly, evidence that this was a common diagnostic dilemma. However, some tumours with a minor papillary component were included in this group, which would almost by definition exclude the possibilities of oncocytoma or eosinophilic chromophobe. The distinction between low-grade oncocytic tumours is challenging, as evidenced in a comprehensive survey detailing the differing opinions of expert urological pathologists regarding the interpretation of a variety of morphological and immunohistochemical features. 21 As oncocytoma is recognised as a benign entity, criteria for this diagnosis have generally been quite stringent, and so it is likely that cases where the diagnosis is favoured strongly are nonetheless not so designated. This has become a particularly challenging area in needle biopsy diagnosis. This category of tumours has prompted some pathologists to introduce terminology into the literature such as 'low-grade unclassified RCC' or 'oncocytic neoplasm' preceded by a modifier such as 'low-grade', 'borderline', 'oncocytic neoplasm, favour oncocytoma', among others. 1, 21, 22 A significant proportion of tumours in the oncocytoma/chromophobe RCC-like category were high stage (40% pT3 or pT4) and a lower, but not negligible, number of these had lymph node metastases ( Figure 7) . In renal oncocytoma, fat invasion and involvement of the renal vein have been reported in a small subset of tumours (<5%). Several studies have shown that patients with such findings do not develop metastases or recurrence and that these tumours maintain their benign behavior; nonetheless, it is likely that many such cases end up in an unclassified or uncertain category. [23] [24] [25] Similarly, other recent studies have shown that oncocytic tumours, including oncocytoma and chromophobe RCC, often have a less distinct tumour pseudocapsule, which may correlate with this predilection for oncocytic tumours to intermingle with structures such as perinephric fat or vessels. 26 Therefore, the prognosis of those tumours that are high stage due to fat or vessel invasion, yet without confirmed metastases, remains to be understood more clearly, especially for oncocytic neoplasms.
The oncocytoma/chromophobe RCC-like category also included tumours that are referred to frequently in the literature as 'hybrid' tumours due to overlapping features of renal oncocytoma and eosinophilic chromophobe renal cell carcinoma. Such tumours are described most often in the setting of renal oncocytosis and Birt-Hogg-Dub e syndrome, but can also rarely occur sporadically. These are not recognised in the current WHO classification as a distinct tumour type, and therefore are placed, for the most part, in the RCCU category. Some authors believe that in the setting of renal oncocytosis these represent a distinct tumour entity, while others have hypothesised that such tumours are a manifestation of Birt-Hogg-Dub e syndrome. 27 The possibility of succinate dehydrogenase-deficient renal cell carcinoma also needs to be considered in these cases. The morphology of this tumour has been described in some detail only recently, and until recently most of these cases would probably have been placed in the RCCU category. The differential diagnosis for the papillary RCC-like category included papillary RCC, translocation-associated RCC, clear cell papillary RCC and hereditary leiomyomatosis and RCC. There were several cases which resembled clear cell papillary RCC with low nuclear grade, apically orientated nuclei and papillary structures; however, complete absence of staining for keratin 7 precluded a definitive diagnosis. 30 While translocation-associated RCC can have a wide range of morphological appearances, demonstration of compatible immunohistochemical findings or a known genetic aberration is necessary when assigning this diagnosis. Sometimes the lack of appropriate clinical history precluded a definitive diagnosis. For example, one case had tubulopapillary architecture and large nuclei with nuclear clearing and prominent eosinophilic nucleoli, features that raised the possibility of hereditary leiomyomatosis and RCC. However, a definitive diagnosis was not assigned, given the absence of pertinent clinical history or genetic studies. 31 In cases such as this, a diagnosis of RCCU was assigned and the possibility of a specific diagnosis was addressed in the 'note' portion of the pathology report.
The differential diagnosis for cases included in the collecting duct-like category included collecting duct carcinoma, renal medullary carcinoma, urothelial carcinoma and, less commonly, papillary RCC. All the cases had high-grade cytological features and associated desmoplastic stroma. Urothelial carcinoma was excluded in all cases because of the absence of a urothelial component; however, this distinction can be difficult if the urothelial component is only focal, and because of overlapping immunohistochemical staining for PAX8 in the renal epithelium and upper tract urothelium. 32 In one case, areas which resembled classic collecting duct carcinoma composed the majority of the case but were juxtaposed with a second area with papillary architecture, which raised the possibility of hereditary leiomyomatosis and renal cell carcinoma-associated RCC. Furthermore, distinction between renal medullary carcinoma and collecting duct carcinoma can be challenging in the absence of pertinent history and immunohistochemical studies; young age, sickle cell haemoglobinopathy, positive staining for OCT4, and loss of INI1 expression would all support a diagnosis of renal medullary carcinoma. 33 The morphological categories showed trends related to AJCC pT and pN categories. We divided these categories into three types and found that the majority of cases in group I (oncocytoma/chromophobe RCC-like) and group II (clear cell RCC-like) were low stage (59% and 63%, respectively). In contrast, most cases in the papillary RCC-like category (58%) and all cases within the collecting duct-like and pure sarcomatoid categories were high stage (pT3 or pT4), all of which were grouped into group III. While the number of cases is too small to draw definitive conclusions regarding prognosis, it is clear that RCCU is not uniformly high stage. The prognostic significance of these categories may also vary by institution, depending on how stringently the morphological and immunohistochemical criteria for each subtype of RCC are applied.
We noticed a marked degree of variability in the work-up of tumours diagnosed as RCCU. First and foremost, the cases included in this study were from an approximately 9-year period (2009-16). Therefore, many recently described entities (i.e. succinate dehydrogenase-deficient RCC, eosinophilic, solid and cystic RCC, hereditary leiomyomatosis and RCC, etc.)
were not yet reported. Furthermore, many immunohistochemical stains and fluorescence in-situ hybridization (FISH) studies were not developed and/ or were not widely available for clinical use. We also attributed the variation in work-up partly to differing preferences between attending pathologists. Given the number of cases and widely variable array of approaches, we consider quantification of the number of immunohistochemical stains and FISH studies performed to be misleading. A truly comprehensive and meaningful assessment of each case would require application of a panel of immunohistochemical markers and FISH studies to every case. Furthermore, we acknowledge that given the circumstances just described, there certainly are cases in this group of tumours that may be able to be classified further if additional work-up could be performed today. Overall, the variable initial work-up of the cases included in this study argues that a standard approach to these challenging tumours could be useful. In one study of 63 metastases of RCC without an identifiable subtype, 51% (32 of 63) of cases were able to be classified after the application of a simple panel of immunohistochemical stains [keratin 7, alphamethylacyl-CoA racemase (AMACR)] and FISH assays (chromosome 3p deletion, trisomy of chromosomes 7 and/or 17). 34 The ideal panel would be an algorithm dependent upon the key morphological features of the tumour, and perhaps multiple standardised approaches could be developed in future depending on the predominant morphological category present in a tumour. The 'best practices recommendations' from the ISUP provide an excellent starting-point in their discussion of immunohistochemistry to aid in the classification of renal tumours, as they list recommended stains according to the morphological pattern. 35 Incorporation of recently characterised immunohistochemical stains (i.e. TFE3, SDHB, fumarate hydratase, 2SC) and molecular assays (i.e. TFE3 FISH) could be useful updates for the future. Additional studies regarding the morphological and genetic diversity of the category RCCU and the clinical applications of these findings are needed. Despite not being able to assign these tumours a specific diagnosis, our study highlights the potential of gleaning prognostic information from morphological patterns. Immunohistochemistry may provide additional prognostic information, as one study reported that RCCU tumours that were positive for TFE3 had a worse 5-year cancer-specific survival (15.6% versus 87.5%). 36 Targetable mutations with directed treatment are being discovered continually, so despite the lack of a specific diagnosis, patients may have viable treatment options. [37] [38] [39] Although most trials focus on clear cell RCC, a few have demonstrated that many of the same drugs may still have clinical benefit in nonclear cell RCC to a lesser or unknown degree. [40] [41] [42] [43] [44] The pathogenesis of tumours diagnosed as RCCU is largely unknown. Future studies will probably continue to elucidate the molecular aberrations present in these tumours. Much as in a variety of renal and non-renal primary neoplasms, regardless of diagnosis mutations may serve as prognostic markers or targets for treatment. 38, 39, 45, 46 The only in-depth molecular study of RCCU performed to date described several molecular subtypes (NF2 loss, mTORC1 hyperactive, FH-deficient, ALK translocation) with differential clinical outcomes; however, the number of cases was small.
11
Another applied comparative genomic hybridisation (CGH) and whole exome sequencing to two cases of RCCU with undifferentiated, multinucleated giant cells with eosinophilic cytoplasm. 47 The CGH profiles included 17 gains and 40 losses and whole exome sequencing with Exon BeadChip showed significant differences in the mutational status of 40 genes, implicating a slew of possible biological pathways. 47 A third manuscript performed single nucleotide polymorphism (SNP) arrays on 21 'morphologically challenging' tumours and were able to assign a 'molecular diagnosis' to each case. 48 Overall, the detailed morphological features present in this series of RCCU documents the wide range of appearances of these tumours and underlines that this category may be assigned to a case for a variety of reasons (overlapping morphology, ancillary studies, clinical history). This category of tumours is remarkably heterogeneous in its histopathological findings, nuclear grade and AJCC TNM stage. Despite the fact that prior publications addressing clinical outcome have been weighted heavily towards high-grade, high-stage tumours, we found that more than half the tumours in our cohort (56%) were AJCC pT categories 1 or 2 and 31% were ISUP grade 2. The most common source of diagnostic difficulty in our cohort concerned tumours composed of predominantly eosinophilic cells. This paper underlines the marked heterogeneity of the category of RCCU by describing the wide variety of morphological appearances this lesion may have and by showing that these tumours can be high or low grade/stage.
